Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
DUTASTERIDE
PRO DOC LIMITEE
G04CB02
DUTASTERIDE
0.5MG
CAPSULE
DUTASTERIDE 0.5MG
ORAL
30/100
Prescription
5 ALFA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0149361001; AHFS:
APPROVED
2019-01-09
PRODUCT MONOGRAPH PR DUTASTERIDE (Dutasteride) 0.5 mg Soft Gelatin Capsules Type I and II 5 Alpha-reductase Inhibitor Date of Revision: January 9, 2019 PRO DOC LTÉE 2925 boul. Industriel Laval, Québec H7L 3W9 Submission Control No.: 223246 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................................... 3 CONTRAINDICATIONS ............................................................................................................... 3 WARNINGS AND PRECAUTIONS .............................................................................................. 4 ADVERSE REACTIONS................................................................................................................ 7 DRUG INTERACTIONS .............................................................................................................. 11 DOSAGE AND ADMINISTRATION .......................................................................................... 13 OVERDOSAGE ............................................................................................................................ 14 ACTION AND CLINICAL PHARMACOLOGY ........................................................................ 14 STORAGE AND STABILITY ...................................................................................................... 16 SPECIAL HANDLING INSTRUCTIONS ................................................................................... 16 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................................... 16 PART II: SCIENTIFIC INFORMATION ................................................................................ 17 PHARMACEUTICAL INFORMATION.......................................................................... Διαβάστε το πλήρες έγγραφο